The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Targeting the mitogen-activated protein kinase cascade to treat cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Convergence of Wnt, ß-Catenin, and Cadherin Pathways
Nelson, W. J., & Nusse, R. (2004) · Science · doi:10.1126/science.1094291 · Cited by 2,515
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,901
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211
Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation.
Pagès, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S., & Pouysségur, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8319 · Cited by 984
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Self-citationModelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Molecular interpretation of ERK signal duration by immediate early gene products
Murphy, L. O., Smith, S., Chen, R.-H., Fingar, D. C., & Blenis, J. (2002) · Nature Cell Biology · doi:10.1038/ncb822 · Cited by 929
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
Defective Thymocyte Maturation in p44 MAP Kinase (Erk 1) Knockout Mice
Pagès, G., Guérin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., & Pouysségur, J. (1999) · Science · doi:10.1126/science.286.5443.1374 · Cited by 654
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Self-citationMolecular mechanisms of “detachment-induced apoptosis—Anoikis”
Grossmann, J. (2002) · Apoptosis · doi:10.1023/a:1015312119693 · Cited by 565
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
Gioeli, D. G., Mandell, J. W., Petroni, G. R., Frierson, H. F., & Weber, M. J. (1999) · PubMed · Cited by 541
Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496
High-Intensity Raf Signal Causes Cell Cycle Arrest Mediated by p21 Cip1
Sewing, A., Wiseman, B., Lloyd, A. C., & Land, H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5588 · Cited by 462
Integrating the MAP kinase signal into the G1 phase cell cycle machinery
Roovers, K., & Assoian, R. K. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<818::aid-bies7>3.0.co;2-6 · Cited by 458
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Hyperexpression of mitogen-activated protein kinase in human breast cancer.
Sivaraman, V. S., Wang, H., Nuovo, G. J., & Malbon, C. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119309 · Cited by 451
Structure and regulation of MAPK phosphatases
Farooq, A., & Zhou, M.-M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2003.12.008 · Cited by 451
Map kinase signaling pathways and hematologic malignancies
Platanias, L. C. (2003) · Blood · doi:10.1182/blood-2002-12-3647 · Cited by 432
Ballif, B. A., & Blenis, J. (2001) · PubMed · Cited by 427
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 426
Mechanisms of regulating the Raf kinase family
Chong, H., Vikis, H. G., & Guan, K.-L. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00139-0 · Cited by 405
Yuen, S. T., Davies, H. R., Chan, T. L., Ho, J. W. C., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S. Y., et al. (2002) · PubMed · Cited by 404
Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., & Kolch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389
Anchorage-dependent Cell Cycle Progression
Assoian, R. K. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.1.1 · Cited by 377
Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway
Pumiglia, K. M., & Decker, S. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.448 · Cited by 356
Giroux, S., Tremblay, M., Bernard, D., Cardin-Girard, J.-F., Aubry, S., Larouche, L., Rousseau, S., Huot, J., Landry, J., Jeannotte, L., et al. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80164-x · Cited by 341
Murphy, L. O., MacKeigan, J. P., & Blenis, J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.144-153.2004 · Cited by 336
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Chen, J., Fujii, K., Zhang, L., Roberts, T., & Fu, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141224398 · Cited by 316
Signal transduction from multiple Ras effectors
Katz, M. E., & McCormick, F. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80112-8 · Cited by 299
Rsk1 mediates a MEK–MAP kinase cell survival signal
Shimamura, A., Ballif, B. A., Richards, S. A., & Blenis, J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00310-9 · Cited by 296
Meloche, S. (1992) · Molecular Endocrinology · doi:10.1210/me.6.5.845 · Cited by 290
Negative Regulation of the Serine/Threonine Kinase B-Raf by Akt
Guan, K.-L., Figueroa, C., Brtva, T. R., Zhu, T., Taylor, J., Barber, T. D., & Vojtek, A. B. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61518-8 · Cited by 281
Anchorage-dependent ERK signaling â mechanisms and consequences
Howe, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00260-x · Cited by 281
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP
Matheny, S. A., Chen, C., Kortum, R. L., Razidlo, G. L., Lewis, R. E., & White, M. A. (2004) · Nature · doi:10.1038/nature02237 · Cited by 217
Bakin, R. E., Gioeli, D. G., Sikes, R. A., Bissonette, E. A., & Weber, M. J. (2003) · PubMed · Cited by 201
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
Vicent, S., López-Picazo, J. M., Toledo, G., Lozano, M. D., Torre, W., Garcia-Corchón, C., Quero, C., Soria, J.-C., Martín-Algarra, S., Manzano, R. G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601644 · Cited by 186
Cook, S. J., Aziz, N., & McMahon, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.330 · Cited by 183
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation
Baumann, B., Weber, C. K., Troppmair, J., Whiteside, S., Israel, A., Rapp, U. R., & Wirth, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080583397 · Cited by 177
Searching for the elusive targets of farnesyltransferase inhibitors
Sebti, S. M., & Der, C. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1234 · Cited by 169
MAP kinases in chondrocyte differentiation
Stanton, L.-A., Underhill, T. M., & Beier, F. (2003) · Developmental Biology · doi:10.1016/s0012-1606(03)00321-x · Cited by 169
Liu, A.-X., Du, W., Liu, J.-P., Jessell, T. M., & Prendergast, G. C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6105-6113.2000 · Cited by 158
BRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
Ordered phosphorylation of p42mapk by MAP kinase kinase
Haystead, T., Dent, P., Wu, J., Haystead, C. M. M., & Sturgill, T. W. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80828-5 · Cited by 156
The RAS Effector RIN1 Directly Competes with RAF and Is Regulated by 14-3-3 Proteins
Wang, Y., Waldron, R. T., Dhaka, A., Patel, A., Riley, M. M., Rozengurt, E., & Colicelli, J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.3.916-926.2001 · Cited by 155
Brondello, J., McKenzie, F. R., Sun, H., Tonks, N. K., & Pouysségur, J. (1995) · PubMed · Cited by 154
Signalling pathways in cardiac myocyte hypertrophy.
Sugden, P. H. (2001) · PubMed · Cited by 148
Eisenmann, K. M., VanBrocklin, M. W., Staffend, N. A., Kitchen, S. M., & Koo, H.-M. (2003) · PubMed · Cited by 143
Vial, E., & Marshall, C. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00812 · Cited by 140
Zayzafoon, M., Abdulkadir, S. A., & McDonald, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308158200 · Cited by 137
Donovan, J. C. H., Milic, A., & Slingerland, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106448200 · Cited by 137
Bottazzi, M. E., Zhu, X., Böhmer, R. M., & Assoian, R. K. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.6.1255 · Cited by 135
MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Sebolt–Leopold, J. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384439 · Cited by 123
Self-citationCalipel, A., Lefevre, G. M., Pouponnot, C., Mouriaux, F., Eychène, A., & Mascarelli, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308709200 · Cited by 120
Coutts, A. S., & Murphy, L. C. (1998) · PubMed · Cited by 110
Mitogen-activated protein kinases as potential targets for pain killers.
Ji, R. (2004) · PubMed · Cited by 105
El‐Ashry, D., Miller, D. L., Kharbanda, S., Lippman, M. E., & Kern, F. G. (1997) · Oncogene · doi:10.1038/sj.onc.1201198 · Cited by 104
Serum- and Glucocorticoid-inducible Kinase SGK Phosphorylates and Negatively Regulates B-Raf
Zhang, B.-H., Tang, E., Zhu, T., Greenberg, M. E., Vojtek, A. B., & Guan, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102808200 · Cited by 103
Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention
Herrera, R., & Sebolt, J. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02307-9 · Cited by 93
Self-citationLunghi, P., Tabilio, A., Dall'Aglio, P. P., Ridolo, E., Carlo‐Stella, C., Pelicci, P. G., & Bonati, A. (2003) · Leukemia · doi:10.1038/sj.leu.2403032 · Cited by 87
Meloche, S. (1995) · Journal of Cellular Physiology · doi:10.1002/jcp.1041630319 · Cited by 86
Shapiro, P. S., & Ahn, N. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1788 · Cited by 67
Manzano, R. G., Montuenga, L. M., Dayton, M. A., Dent, P., Kinoshita, I., Vicent, S., Gardner, G. J., Nguyen, P., Choi, Y. H., Trepel, J. B., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205542 · Cited by 64
Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu, K., Hamilton, A. D., & Sebti, S. M. (2003) · PubMed · Cited by 61
Raf pathway inhibitors in oncology.
Bollag, G. E., Freeman, S., Lyons, J. F., & Post, L. E. (2003) · PubMed · Cited by 59
Prognostic relevance of MAPK expression in glioblastoma multiforme
Mawrin, C., Diete, S., Treuheit, T., Kropf, S., Vorwerk, C. K., Boltze, C., Kirches, E., Firsching, R. P., & Dietzmann, K. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.3.641 · Cited by 57
Meng, X. W., Chandra, J., Loegering, D. A., Becelaere, K. V., Kottke, T. J., Gore, S. D., Karp, J. E., Sebolt-Leopold, J., & Kaufmann, S. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304793200 · Cited by 54
Self-citationJørgensen, K., Holm, R., Mælandsmo, G. M., & Flørenes, V. A. (2003) · PubMed · Cited by 41
Colorectal tumors frequently express phosphorylated mitogen‐activated protein kinase
Lee, S. H., Lee, J. W., Soung, Y. H., Kim, S. Y., Nam, S. W., Park, W. S., Kim, S. H., Yoo, N. J., & Lee, J. Y. (2004) · Apmis · doi:10.1111/j.1600-0463.2004.apm11204-0502.x · Cited by 36
Ras signaling: PP2A puts Ksr and Raf in the right place
Raabe, T., & Rapp, U. R. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00568-2 · Cited by 34
Barron, A., FINN, S. G., & Fuller, S. J. (2003) · Biochemical Journal · doi:10.1042/bj20021395 · Cited by 29
Wang, H., & Chakrabarty, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206348 · Cited by 28
Milella, M., Kornblau, S. M., & Andreeff, M. (2003) · PubMed · Cited by 25
Preclinical development of ARRY-142886, a potent and selective MEK inhibitor
Wallace, E. M., Yeh, T. C., Lyssikatos, J., Winkler, J., Lee, P., Marlow, A., Hurley, B., Marsh, V., Bernat, B. A., Evans, R. M., et al. (2004) · Cancer Research · Cited by 18
Hilger, R. A., Kredke, S., Hedley, D. W., Moeller, J. G., Bauer, R. J., Stellberg, W., Seeber, S., Scheulen, M. E., & Strumberg, D. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40567 · Cited by 17
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Meloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091
Metadata
- Authors
- Sebolt-Leopold, J. S., & Herrera, R.
- Venue
- Nature Reviews Cancer
- Published
- 2004-12
- Volume
- 4
- Issue
- 12
- Pages
- 937-947
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2041098455
- Cited by
- 1,108
- References
- 96
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.